Cost-effectiveness analysis: Risk stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the primary care physician using the NAFLD fibrosis score

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Tapper, Elliot B ^a   Hunink, M G Myriam ^b,c   Afdhal, Nezam H ^a   Lai, Michelle ^a   Sengupta, Neil ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ELASTOGRAPHY; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; PREVALENCE; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; COMPLICATION; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; ECONOMICS; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATIENT REFERRAL;

COST-BENEFIT ANALYSIS; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSICIANS, PRIMARY CARE; REFERRAL AND CONSULTATION; RISK ASSESSMENT;

EID: 84960498829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147237     Document Type: Article

References (41)

1. Afdhal NH (2012) Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? JAMA 308:608-616. doi: 10. 1001/jama.2012.8402 PMID: 22760235
2. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. (2013) Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988.1994. American journal of epidemiology 178:38-45. doi: 10.1093/aje/kws448 PMID: 23703888
3. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:1179-1187. e1173. doi: 10.1053/j.gastro.2012.08.002 PMID: 22885331
4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005-2023. doi: 10.1002/hep. 25762 PMID: 22488764
5. Festi D, Schiumerini R, Marzi L, Di Biase A, Mandolesi D, Montrone L, et al. (2013) Review article: the diagnosis of non-alcoholic fatty liver disease.availability and accuracy of non-invasive methods. Alimentary pharmacology & therapeutics 37:392-400.
6. Younossi ZM, Zheng L, Stepanova M, Henry L, Venkatesan C, Mishra A (2015) Trends in outpatient resource utilizations and outcomes for medicare beneficiaries with nonalcoholic fatty liver disease. Journal of clinical gastroenterology 49:222-227. doi: 10.1097/MCG.0000000000000071 PMID: 24637730
7. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. (2015) Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149:389-397. doi: 10.1053/j.gastro. 2015.04.043 PMID: 25935633
8. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547-1554. doi: 10.1002/hep. 27368 PMID: 25125077
9. Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. New England Journal of Medicine 344:495-500. PMID: 11172192
10. Tapper EB, Sengupta N, Hunink MM, Afdhal NH, Lai M (2015) Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. The American journal of gastroenterology 110:1298-1304. doi: 10.1038/ajg.2015.241 PMID: 26303130
11. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846-854. PMID: 17393509
12. Tapper EB, Castera L, Afdhal NH (2015) FibroScan (Vibration Controlled Transient Elastography): Where does it stand in the US practice. Clinical Gastroenterology and Hepatology 13:27-36. doi: 10. 1016/j.cgh.2014.04.039 PMID: 24909907
13. Kwok R, Choi KC, Wong GL-H, Zhang Y, Chan HL-Y, Luk AO-Y, et al. (2015) Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut: gutjnl-2015-309265.
14. Doycheva I, Cui J, Nguyen P, Costa E, Hooker J, Hofflich H, et al. (2015) Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Alimentary Pharmacology & Therapeutics.
15. Hunink MGMWM, Wittenberg E, Drummond MF, Pliskin JS, Wong JB, Glasziou PP (2014) Decision making in health and medicine: Integrating evidence and values. Cambridge, UK: Cambridge University Press.
16. Petrou S, Gray A (2011) Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. Bmj 342.
17. Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for reporting cost-effectiveness analyses. JAMA 276:1339-1341. PMID: 8861994
18. Dowman JK, Tomlinson J, Newsome P (2011) Systematic review: the diagnosis and staging of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics 33:525-540.
19. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine 362:1675-1685. doi: 10.1056/NEJMoa0907929 PMID: 20427778
20. Adams LA, Sanderson S, Lindor KD, Angulo P (2005) The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. Journal of hepatology 42:132-138. PMID: 15629518
21. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clinical Gastroenterology and Hepatology 13:643-654. e649. doi: 10.1016/j.cgh.2014.04.014 PMID: 24768810
22. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE (2004) Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39:1647-1654. PMID: 15185306
23. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:121-129. doi: 10.1002/hep. 23276 PMID: 19827166
24. Sabaté E (2003) Adherence to long-term therapies: evidence for action: World Health Organization.
25. Singal AG, Pillai A, Tiro J (2014) Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 11:e1001624. doi: 10. 1371/journal.pmed.1001624 PMID: 24691105
26. Tapper EB, Krajewski K, Lai M, Challies T, Kane R, Afdhal N, et al. (2014) Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterol Rep (Oxf).
27. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128:1898-1906. PMID: 15940625
28. ®. Journal of hepatology 56:833-839. doi: 10.1016/j.jhep. 2011.10.017 PMID: 22173167
29. Kwok R, Tse YK, Wong GH, Ha Y, Lee A, Ngu M, et al. (2014) Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease.the role of transient elastography and plasma cytokeratin-18 fragments. Alimentary pharmacology & therapeutics 39:254-269.
30. Wong VW-S, Vergniol J, Wong GL-H, Foucher J, Chan AW-H, Chermak F, et al. (2012) Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. The American journal of gastroenterology 107:1862-1871. doi: 10.1038/ajg.2012.331 PMID: 23032979
31. Petta S, Vanni E, Bugianesi E, Di Marco V, Camma C, Cabibi D, et al. (2015) The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver International 35:1566-1573. doi: 10.1111/liv. 12584 PMID: 24798049
32. Neumann PJ, Cohen JT, Weinstein MC (2014) Updating cost-effectiveness.the curious resilience of the $50, 000-per-QALY threshold. New England Journal of Medicine 371:796-797. doi: 10.1056/NEJMp1405158 PMID: 25162885
33. Mehrotra A, Forrest CB, Lin CY (2011) Dropping the baton: specialty referrals in the United States. Milbank Quarterly 89:39-68. doi: 10.1111/j.1468-0009.2011.00619.x PMID: 21418312
34. Forrest CB, Shadmi E, Nutting PA, Starfield B (2007) Specialty referral completion among primary care patients: results from the ASPN Referral Study. The Annals of Family Medicine 5:361-367. PMID: 17664503
35. Tapper EB, Sengupta N, Lai M, Horowitz G (2016) Understanding and Reducing Ceruloplasmin Overuse with a Decision Support Intervention for Liver Disease Evaluation. The American Journal of Medicine 129:e17.22.
36. Tapper EB, Patwardhan VR, Curry M (2014) Low Yield and Utilization of Confirmatory Testing in a Cohort of Patients with Liver Disease Assessed for Alpha-1 Antitrypsin Deficiency. Digestive diseases and sciences: 1-6.
37. Tapper EB, Rahni DO, Arnaout R, Lai M (2013) The overuse of serum ceruloplasmin measurement. The American journal of medicine 126:926.e921-926.e925.
38. Tapper EB, Afdhal NH (2015) Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Current opinion in gastroenterology 31:192-198. doi: 10. 1097/MOG.0000000000000169 PMID: 25730177
39. Petta S, Maida M, Macaluso FS, Di Marco V, Cammà C, Cabibi D, et al. (2015) The Severity of Steatosis Influences Liver Stiffness Measurement in Patients with Nonalcoholic Fatty Liver Disease. Hepatology 62:1101-1110. doi: 10.1002/hep. 27844 PMID: 25991038
40. Tapper EB, Cohen EB, Patel K, Bacon B, Gordon S, Lawitz E, et al. (2012) Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clinical Gastroenterology and Hepatology 10:932-937. e931. doi: 10.1016/j.cgh. 2012.01.015 PMID: 22289876
41. De Lédinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart J-B, Cassinotto C, et al. (2014) Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. Journal of hepatology 60:1026-1031. doi: 10.1016/j.jhep. 2013.12.018 PMID: 24378529